A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma—Application to a Pharmacokinetic Study

A Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Bioanalytical Method for the Quantification of Encorafenib and Binimetinib as a First-Line Treatment for Advanced (Unresectable or Metastatic) Melanoma—Application to a Pharmacokinetic Study

The combination regimen targeting BRAF and MEK inhibition, for instance, encorafenib (Braftovi<sup>™</sup>, ENF) plus binimetinib (Mektovi<sup>®</sup>, BNB), are now recommended as first-line treatment in patients with unresectable or metastatic melanoma with a BRAF V600-acti...

Full description

Bibliographic Details
Main Authors: Mohamed M. Hefnawy, Mohammed M. Alanazi, Abdullah M. Al-Hossaini, Abdulaziz I. Alnasser, Adel S. El-Azab, Yousef A. Bin Jardan, Mohamed W. Attwa, Manal A. El-Gendy
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Molecules
Subjects:
LC–MS/MS
melanoma
encorafenib
binimetinib
rat plasma
pharmacokinetics
Online Access:https://www.mdpi.com/1420-3049/28/1/79

Internet

https://www.mdpi.com/1420-3049/28/1/79

Similar Items